Zinpentraxin Alfa

Summary

Zinpentraxin Alfa (CHEMBL4297814) is a phase-3 clinical-stage protein; indicated across 6 conditions including idiopathic pulmonary fibrosis and acquired polycythemia vera.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 6 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297814
Name	Zinpentraxin Alfa
Type	Protein
Max phase	3

Also known as: Pentraxin 2 (human), Pentraxin-2, Prm-151, PRM-151, Ptx-2, Recombinant human pentraxin 2, Recombinant human pentraxin-2, Recombinant human serum amyloid p, RG-30326, RG-6354, RG30326, RG6354

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
idiopathic pulmonary fibrosis	3	MONDO:0800504	EFO:0000768
acquired polycythemia vera	2	MONDO:0009891	EFO:0002429
primary myelofibrosis	2	MONDO:0009692	EFO:0002430
glaucoma	2	MONDO:0005041	MONDO:0005041
pulmonary fibrosis	1	MONDO:0002771	EFO:0009448

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01064817	PHASE2	COMPLETED	PRM-151 in the Prevention of Scarring Following Trabeculectomy
NCT01981850	PHASE2	COMPLETED	A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
NCT02550873	PHASE2	COMPLETED	A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT01254409	PHASE1	COMPLETED	A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).